Actively Recruiting
Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial
Led by Medical University Innsbruck · Updated on 2026-03-16
2070
Participants Needed
8
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether a faster hospital discharge after invasive treatment for acute myocardial infarction (heart attack) is as safe as the standard longer stay. This trial compares a fast discharge strategy, where patients leave the hospital about 24 hours after treatment, to the usual care of staying more than 36 hours. The study aims to find out if early discharge increases the risk of major heart-related problems over a year following the heart attack. Participants are randomly assigned to one of two groups: one group receives standard care with discharge after more than 36 hours, while the other group is discharged early at around 24 hours following invasive management. This approach includes patients who had successful procedures to open blocked heart arteries. The trial is conducted at multiple centers and monitors patients for up to 12 months after randomization. During the study, participants will be regularly assessed for major adverse cardiovascular events such as heart attacks, strokes, hospital readmissions, bleeding events, and death from any cause. Researchers will also measure hospital stay length, healthcare costs, and treatment adherence. Follow-up includes monitoring these outcomes up to 12 months after the initial treatment to evaluate the safety and impact of the faster discharge plan.
CONDITIONS
Brief Title
Fast Discharge After Acute Myocardial Infarction Discharge MI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
- Age 18 years or older at time of consent
- Underwent invasive management with successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
- Ability to understand and willing to sign written informed consent
You will not qualify if you...
- Myocardial infarction complicated by cardiac arrest (out-of-hospital or in-hospital)
- PCI-related complications such as coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, severe allergic reaction, stroke or thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage, arterial dissection/occlusion or emboli
- Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (<50 beats per minute) after PCI
- Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate, need for inotropes or vasopressors)
- Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
- Ongoing disorders of consciousness (somnolence, sopor, coma)
- Acute kidney injury defined by KDIGO stages 2 and 3
- Pregnancy
- Untreated critical non-culprit lesions requiring revascularization during index hospitalization preventing fast discharge
- Immobility or social circumstances preventing fast discharge as assessed by care team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Hospital stay of approximately 1 to 2 days depending on discharge strategy
Participants undergo invasive management for acute myocardial infarction followed by discharge according to their assigned care strategy: either fast discharge at about 24 hours or standard discharge after more than 36 hours.
1 hospital stay
Duration - Up to 12 months
Participants are monitored for safety and major adverse cardiovascular events for up to 12 months after discharge.
Visits scheduled throughout the 12-month follow-up period
Trial Site Locations
Total: 8 locations
1
Hospital Wiener Neustadt
Wiener Neustadt, Lower Austria, Austria, 2700
Actively Recruiting
2
Cardinal Schwarzenberg Hospital Schwarzach
Schwarzach im Pongau, Schwarzach Im Pongau, Austria, 5620
Not Yet Recruiting
3
Paracelsus Medical University Salzburg
Salzburg, State of Salzburg, Austria, 5020
Actively Recruiting
4
Medical University of Graz
Graz, Styria, Austria, 8010
Actively Recruiting
5
Medical University of Innsbruck
Innsbruck, Tyrol, Austria, 6020
Actively Recruiting
6
University Teaching Hospital Wels-Grieskirchen
Wels, Upper Austria, Austria, 4600
Actively Recruiting
7
Academic Teaching Hospital Feldkirch
Feldkirch, Vorarlberg, Austria, 6800
Actively Recruiting
8
Ludwig Maximilian University Munich
Munich, Bavaria, Germany, 81377
Not Yet Recruiting
Research Team
M
Martin Reindl, MD, PhD
I
Ivan Lechner, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here